News Archive

Cedar Associates Announces Publication of Key Paper Reporting on the VA Precision Oncology Program

February 2016
Access Article Here

Biodesix Receives BCBS Coverage for VeriStrat

March 2015
Cedar’s research, published in the journals Lung Cancer and Current Medical Research and Opinion, found that the Veristrat test decreased total lifetime direct cost by $135 per patient and significantly influenced therapy recommendations. Cedar Associates is proud to be a part of Biodesix’s success.

Proliferative epithelial disease identified as breast cancer risk factor

February 2015
Proliferative epithelial disease found in nipple aspirate fluid is an independent risk factor for developing breast cancer, comparable to that posed by a family history of the disease. Authors discuss the implications of this finding on risk prediction and clinical decision-making concerning breast cancer surveillance and chemoprevention.
Access Article Here

Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer

December 2014
Prior economic analysis predicted that a 12-gene assay would improve patient outcomes and lower medical costs for individuals with stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer. A group of researchers, including members of the Mayo Clinic and Cedar Associates, assessed the validity of this prediction by comparing clinicians’ adjuvant chemotherapy (aCT) recommendations before and after knowing the results of the 12-gene assay. Analysis of the data, collected from 17 Mayo Clinic cancer research sites, confirmed that use of the 12-gene assay reduced direct medical costs and improved patients’ wellbeing.
Access Article Here

Mayo Clinic, Cedar researchers analyze impact of treatment-resistant depression

August 2014
A team of researchers at the Mayo Clinic and at Cedar Associates assessed the burden of treatment-resistant depression—depression that fails to respond to one or more rounds of treatment with drug therapy. They compiled published data about the clinical, societal, and economic outcomes of treatment-resistant depression. The annual US cost of treatment-resistant depression is $29-$48 billion, contributing approximately one-fourth to the total costs of major depression ($106-$118 billion).
Access Article Here

Influence of a genomic classifier on postoperative treatment decisions in high-risk prostate cancer patients: Results from the PRO-ACT study

May 2014
After undergoing radical prostatectomy (RP), patients remain at risk of metastasis. An individualized genomic classifier (GC) test designed to predict metastases significantly changes urologists’ adjuvant treatment recommendations for post-operative patients with prostate cancer. This study shows how the GC test may guide the use of adjuvant radiation in patients after undergoing radical prostatectomy.
Access Article Here

Cedar publication cited in amicus brief presented to the U.S. Supreme Court

August 2005
Cedar’s publication, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph node-negative, estrogen receptor-positive, early stage breast cancer, was cited in an amicus brief presented to the U.S. Supreme Court by the Biotechnology Industry Organization to substantiate the value of personalized medicine and the need for patent protection for novel diagnostic technologies.
Access amicus brief here